Vaccinations

UK invests billions in new biosecurity centre to strengthen pandemic preparedness

UK invests billions in a National Biosecurity Centre in Essex: Europe’s largest hub for vaccine development, and pandemic preparedness.

COVID-19: The challenge of healthcare logistics

Zisis Kozlakidis, International Agency for Research on Cancer, with Erik Steinfelder, Thermo Fisher Scientific, chart the challenges in healthcare logistics in relation to COVID-19.

AstraZeneca vaccine cannot stop the South African mutation

The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.

UK Government and CureVac partnership to tackle COVID-19 virus variants

The UK Government and vaccine manufacturer CureVac have partnered to rapidly develop new vaccines in response to new COVID-19 virus variants.

UK regulator assures safety of COVID-19 vaccines

Recent data published by the UK’s independent medicines regulator assures the Pfizer/BioNTech and the Oxford University/AstraZeneca vaccines meet strict regulatory standards for safety

Scientists invent AI that creates COVID vaccine candidates within seconds

Scientists usually take months to analyse potential mutations of the virus, but this new AI can create COVID vaccine candidates within seconds.

Over 10 million people receive COVID-19 vaccine

UK reaches significant milestone as more than 10 million people receive the first dose of the COVID-19 vaccine.

Clinical trial looks into mixing different COVID-19 vaccines

A world-first clinical trial looking into mixing different COVID-19 vaccine doses has been backed by £7 million of government funding.

Israel will give Palestinian doctors their first 5,000 vaccines

Israel has agreed to give the first 5,000 vaccine doses to Palestinian medical workers - but only if they live in annexed east Jerusalem, while the West Bank and Gaza remain without vaccines.

Sputnik V vaccine is 91.6% effective against COVID

Interim data from Phase 3 clinical trials show that Russia's Sputnik V vaccine is capable of a 91.6% efficacy against COVID-19.

Research says 12 weeks between AstraZeneca doses improves protection

AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.

How to handle vaccine hesitancy at work

Alan Price, CEO at BrightHR, discusses how employers and HR departments can handle vaccine hesitancy in the workplace.

All UK adults could be offered COVID vaccine by May

According to recent reports, all UK adults could have their first dose of the COVID vaccine by May, 2021 - opening up the potential of a real summer.

High infection numbers can undo our vaccination programmes

The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.

UK purchases additional 40 million doses of Valneva vaccine

The UK government has announced that it has secured early access to a further 40 million doses of the Valneva COVID-19 vaccine.

Third of Americans say they are unlikely to get COVID-19 vaccine

A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.

Johnson & Johnson vaccine has 66% efficiency in one dose

New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders